mots c

Regeneration vs degeneration — where this fits

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why it would work (logic chain)

No mechanism chain catalogued yet.

How many people take it

There is no reliable global count of how many people take this compound. That number is not in this ledger.

What we can count from this ledger:

• 0 anecdote source(s) (posts, threads, comments)
• 0 anecdote-tier claim(s) derived from them

Logic: Without catalogued Reddit/X posts, this article cannot answer how many people take it — only what studies exist.

Evidence inventory

This is a count of what is in this ledger — not a claim about all research worldwide.

• Scientific sources catalogued (PubMed, trials, reviews): 8
• Claims tagged human evidence: 0
• Claims tagged preclinical (animal/lab): 0
• Claims tagged anecdotal: 0
• Reddit posts catalogued: 0
• X posts catalogued: 0
• Other anecdote sources (YouTube, Instagram, etc.): 0
• Total sources in chain: 8

Logic: Studies exist in the ledger, but none are graded as strong human proof for the uses people discuss online. Animal and lab work is not the same as proof in people.

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.2 / 1.00 — low — animal and anecdote heavy

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (MOTS-MET) (source s1)

Ongoing Phase 2a randomized double-blind placebo-controlled trial started in 2026 testing MOTS-c for insulin sensitivity in prediabetes and obesity.

Evidence type: Published research.

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner (source s2)

2026 study showing MOTS-c improves skeletal muscle mitochondrial function via PGC-1α/AMPK in mice, reduces ROS, without changing respiratory protein content.

Evidence type: Published research.

Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss (source s3)

2025 study finding elevated circulating MOTS-c in obesity linked to metabolic issues, unchanged post-weight loss, suggesting compensatory response.

Evidence type: Published research.

Reduced serum levels of mitochondria-derived peptide MOTS-c in patients with type 2 diabetes mellitus (source s4)

2025 paper on reduced serum MOTS-c levels in T2DM patients.

Evidence type: Published research.

Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (source s5)

2025 review/paper on MOTS-c reducing pancreatic islet senescence in mouse models and potential as senotherapeutic for diabetes.

Evidence type: Published research.

Exploring the therapeutic potential of MOTS-c in age-related macular degeneration (source s6)

2025 PubMed article on MOTS-c therapeutic potential in age-related macular degeneration (AMD).

Evidence type: Published research.

Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion (source s7)

2025 study linking endurance training, MOTS-c secretion, and improved muscle mitochondrial function via AMPK/PGC-1α.

Evidence type: Published research.

Reduced serum levels of mitochondria-derived peptide MOTS-c in patients with obstructive sleep apnea (source s8)

2025 study on reduced serum MOTS-c levels in OSA patients.

Evidence type: Published research.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.